Back to Sectors

ALLR

Allarity Therapeutics, Inc.
3 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 70% | 3/30/2026 | margin expansionBULLISH | 50% | 3/30/2026 | buybackBEARISH | 80% | 3/30/2026 | dilution riskBULLISH | 60% | 3/30/2026 | regulatory actionBULLISH | 60% | 3/30/2026 | capital raiseBULLISH | 70% | 5/15/2026 | capital raiseBULLISH | 40% | 5/15/2026 | margin expansionBEARISH | 60% | 5/15/2026 | debt restructureBULLISH | 30% | 5/15/2026 | buybackBULLISH | 70% | 5/15/2026 | capital raiseBULLISH | 40% | 5/15/2026 | margin expansionBEARISH | 60% | 5/15/2026 | debt restructureBULLISH | 30% | 5/15/2026 | buybackMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 15

Raised $20 million through promissory notes to extend clinical runway.

capital raise
70%
bullishMay 15

Total operating expenses decreased approximately 10% year-over-year.

margin expansion
40%
bearishMay 15

New debt carries high 9% interest and restrictive redemption triggers.

debt restructure
60%
bullishMay 15

Implemented share repurchase program with $4.9 million remaining authorization.

buyback
30%
bullishMay 15

Raised $20 million through promissory notes to extend clinical runway.

capital raise
70%
bullishMay 15

Total operating expenses decreased approximately 10% year-over-year.

margin expansion
40%
bearishMay 15

New debt carries high 9% interest and restrictive redemption triggers.

debt restructure
60%
bullishMay 15

Implemented share repurchase program with $4.9 million remaining authorization.

buyback
30%
bullishMar 30

G&A expenses reduced by 45% year-over-year through operational streamlining.

margin expansion
70%
bullishMar 30

Board authorized $5M share repurchase program to signal valuation support.

buyback
50%
bearishMar 30

Heavy reliance on ATM and debt facilities to fund operations until 2027.

dilution risk
80%
bullishMar 30

Received FDA Fast Track designation for stenoparib in Q3 2025.

regulatory action
60%
bullishMar 30

Secured $20 million in promissory notes from Streeterville Capital in March 2026.

capital raise
60%

Filing History

10-QMay 15, 2026

The Q1 2026 filing presents a company at a crossroads, balancing a promising technological breakthrough against a tightening financial vise. The issuance of the DRP patent notice is a clear fundamental win that validates the company's precision medicine approach and potentially lowers the cost of future clinical trials. However, the financial engineering used to fund this progress—specifically the use of high-interest, restrictive promissory notes—creates a volatile risk profile for investors. Ultimately, the impact of this filing depends on the speed of clinical execution. If Allarity can leverage its patented diagnostic to hit Phase II milestones rapidly, it may attract the non-dilutive funding or partnerships necessary to survive. Conversely, if the restricted nature of its cash and the looming debt redemptions outpace its clinical progress, the company faces a severe liquidity crunch that could erode shareholder value through emergency equity offerings.

10-KMar 30, 2026

The 10-K paints a picture of a high-stakes binary bet. Allarity has successfully cleared its legacy liabilities and streamlined its cost structure, transforming into a focused clinical-stage entity. The synergy between stenoparib and the DRP platform offers a legitimate path to precision oncology, provided the upcoming Phase 2 data can replicate early signals of durable response in a larger, biomarker-selected cohort. However, the investment risk remains extreme. The company is operating against a ticking clock, with a runway that expires in early 2027 and a capital structure burdened by heavy milestone obligations. Investors are essentially weighing the potential of a breakthrough in ovarian cancer against the very real possibility of a liquidity event or license termination. The outcome now rests entirely on the ability to execute the redesigned Phase 2 trial and secure additional financing before the cash runs dry.